Complementing resources already available, PCSK9 Forum is pleased to announce the next in this series of educational slide decks which focus on a novel approach to PCSK9 inhibition. Inclisiran is a synthetic small interfering RNA (siRNA) therapeutic that specifically inhibits PCSK9 synthesis in hepatocytes. As inclisiran is long-acting, dosing is more infrequent than for monoclonal antibodies, suggesting practical and logistical advantages for routine practice.

PCSK9 inhibition: an overview of therapeutic approaches: This deck discusses current approaches to PCSK9 inhibition and how inclisiran differs.

Inclisiran and the ORION clinical development program: This deck will bring clinicians up to date with results from phase II/III trials in the ORION program with inclisiran.

Bookmark PCSK9 Forum to return for regular updates to this innovative expert-led educational slide resource programme.